Clinical Trial Update: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ODM-208

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Prostate Cancer Metastatic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING